Biomedical subjects

C Brunckhorst

Publications and source records attributed to C Brunckhorst.

8 recordsLinked to original sources

PubMed2005

Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre.

OBJECTIVE: To investigate the predictors for adverse clinical outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) during long term follow up. METHODS: 61 patients with ARVD/C were studied to assess the impact of family history, clinical findings, surface ECG parameters, echocardiographic findings, and electrophysiological findings on clinical outcome. The prevalence of these risk factors were compared in two patient groups: group A (patients with adverse clinical outcome: sudden cardiac death, death from heart failure, or heart transplant) and group B (survivors excluding patients who received a heart transplant). RESULTS: Mean age at first diagnosis was 44 (14) years. The mean follow up duration was 55 (47) months. Ten patients (16%) died during follow up. The cause of death of eight of these patients was probably arrhythmic. Two patients died of advanced heart failure. Five patients underwent heart transplantation because of terminal heart failure. Risk factors significantly associated with adverse outcome were history of congestive heart failure (p < 0.001), the presence of left ventricular involvement on echocardiography (p < 0.001), left atrial dilatation (p < 0.05), prolonged PR duration (p < 0.01), prolonged QRS in V1 (p < 0.05), and bundle branch block (p < 0.05). In multivariate analysis, history of congestive heart failure and presence of left ventricular involvement were identified as independent risk predictors for an adverse outcome. CONCLUSIONS: Congestive heart failure and left ventricular involvement are independently associated with adverse outcome in patients with ARVD/C during long term follow up.

Adult↗

PubMed2004

[Ventricular tachycardia--etiology, mechanisms and therapy].

Prevention and therapy of cardiovascular diseases have undergone enormous changes over the last decades. However, ventricular tachycardias (VT) still pose a major problem in a number of cardiac patients. Analysis of the etiology and mechanism of the tachycardia is of paramount importance for initiation of specific therapies. The morphology of VTs on the surface ECG can be either polymorphic or monomorphic. Polymorphic VTs have a constantly changing QRS-morphology due to the variable ventricular activation, without specific origin. This kind of VT is mainly caused by an acute, often reversible condition, such as ischemia or QT-prolongation. These VTs are potentially malignant, they cannot be treated by catheter ablation. In contrast, monomorphic VTs have a constant QRS-morphology, indicative of repetitive ventricular depolarisation in the same activation sequence. This kind of VT is either caused by focal abnormal activity (triggered activity, automaticity, micro-reentry) or by an arrhythmogenic substrate (macro-reentry). Focal idiopathic VTs usually have a benign prognosis and catheter ablation is potentially curative. The majority of ventricular arrhythmias, however, are substrate-related reentry tachycardias, most commonly based on an infarct scar Therapy of first choice for these patients is the treatment with an implantable Cardioverter/Defibrillator (ICD). Catheter ablation is indicated in case of drug refractory recurrent VTs triggering repeated ICD therapies. The different therapeutic strategies are not alternative but complementary options in many patients.

Algorithms↗

PubMed2004

[ICD therapy in patients with coronary artery disease--incidence of adequate interventions].

BACKGROUND: The Implantable Cardioverter/Defibrillator (ICD) represents the therapy of choice for patients at risk of malignant ventricular arrhythmias. The survival benefit of the ICD vs antiarrhythmic therapy in patients with coronary artery disease and ventricular tachycardia has been proven. Recently, the ICD therapy has also been established for primary prevention in high risk patients. We report about the incidence of adequate ICD therapies in patients with coronary artery disease, who underwent ICD implantation at the University Hospital Zurich. METHODS: 104 consecutive patients (97 men, 7 women, mean age of 67 +/- 10 years) with coronary artery disease, who underwent ICD implantation in accordance with the AHA/ACC/NASPE guidelines between January 2000 and July 2003 were included in the study. Follow-up was performed every three to six months, when all ICD therapies were documented. This documentation was used for analysis of adequate or inadequate ICD therapies. RESULTS: The mean follow-up time was 383 +/- 195 days. The time to the first adequate therapy was 201 +/- 283 days. The cumulative incidence for the first adequate therapy was 21% at six months, 39% at two years and 59% at four years. In 64% of patients, who experienced adequate ICD therapies, antitachycardia pacing (ATP) and in 36% an initial shock was delivered. ATP was successful in 83% of adequately delivered episodes. In the follow-up period 12 patients died. CONCLUSION: The benefit of the ICD was apparent in patients at risk for ventricular arrhythmias and coronary artery disease after a relatively short period of time, which underlines the important role of the ICD in primary and secondary prevention.

Aged↗

PubMed2004

[Psychopharmaceuticals and arrhythmias].

Psychoactive drugs have been associated with arrhythmia for 40 years. Torsades de pointes was originally seen in patients with pre-existing heart disease or with intoxication. Now, there is increasing awareness that drugs used for non-antiarrhythmic and non-cardiovascular indications can exert significant effects on repolarisation and may cause ventricular tachycardia. Most of the drugs that prolong the QT-interval incorporate blockade of the potassium channel Ikr in their spectrum. Among psychotrophic drugs the low-potency phenothiazines have most often been implicated, particularly thioridazine. For the high-potency phenothiazines and butyrophenones there are fewer reports on serious arrhythmia. More recently the atypical antipsychotics have been introduced. Although some of them increase the QT-interval considerably arrhythmic events seem to be a very rare problem with the atypical antipsychotics available. Drugs acting as class I antiarrhythmics such as tricyclic antidepressants are not recommended after myocardial infarction. Selective serotonin reuptake inhibitors seem to be safe. Patients with a prolonged QT-interval or patients that experienced Torsade de pointes are at a considerable higher risk upon exposition to a QT-prolonging drug. Drug interactions played a role in many fatalities with QT-prolonging drugs and are important.

Antidepressive Agents, Tricyclic↗

PubMed2003

[Catheteer ablation technique of atrial fibrillation].

Atrial fibrillation is the most frequent arrhythmia with a prevalence of 1.7% in the general population and 5% in the population over 65 year old [1], the prevalence in men over 65 years is even 9.1% [2]. Atrial fibrillation is divided dependent on its frequency in intermittent, persisting and chronic. The symptoms and the clinical course are individually very different. Responsible for the initiation of atrial fibrillation are triggers, which initiate atrial fibrillation, and a substrate, that means an atrial myocardium altered by remodelling, which maintains atrial fibrillation. A curative treatment was not available until recently. Different ablation techniques were developed: Linear, focal ablation techniques and the isolation of pulmonary veins. The observation that atrial fibrillation will maintain only in large atria, led to the linear ablation techniques with the goal of reducing the atria functionally. The linear ablations have however a small value because of low success rates and high complication rates. Arrhythmogenic foci are of crucial importance in the initiation of atrial fibrillation, these foci are mostly located in the pulmonary veins. This observation led to the focal ablation in the pulmonary veins, which was left again because of the limitations, however. For some years the isolation of pulmonary veins is performed at some large centers. This paper summarizes the most important techniques, success rates and complications of the pulmonary vein isolation. The present indication and the preinterventional diagnostics are discussed. Due to the constantly improving success rates and decreasing complication rates (pulmonary vein stenosis, thrombembolie, cardiac tamponades, mortality practically) the pulmonary vein isolation is an alternative possibility of treatment which can be considered for a subgroup of patients with drug-resistant, symptomatic atrial fibrillation.

Atrial Fibrillation↗

PubMed2002

[Radiofrequency catheter ablation of ventricular tachycardias].

Management of patients with ventricular tachycardia (VT) is often difficult. Drug therapy is often ineffective. Implantable cardioverter defibrillators (ICDs) can terminate VT episodes but do not prevent them. Radiofrequency (RF) catheter ablation can suppress arrhythmias in selected patients. However, the procedure is often challenging and success rates lower than for ablation of supraventricular tachycardias. The mapping and ablation approach depends on the VT mechanism. Monomorphic VT in patients without structural heart disease is referred to as idiopathic and has a focal origin. These VTs can be abolished by ablation in most of the patients. In VT due to reentry within an area of scar from an old myocardial infarction or cardiomyopathic process, critical parts of the circuit may be difficult to localize, rendering RF ablation challenging. In patients with monomorphic VT, prevention of VT recurrence can be achieved in 55% to 80% of patients. Multiple morphologies of VTs and circuits that are located deep in the endocardium are common problems that reduce efficacy. Furthermore, mapping to identify target regions for ablation can be more difficult if VT is rapid and not tolerated, or not inducible. Recently, multisite mapping of the arrhythmia substrate during sinus rhythm or multisite activation mapping of a few VT beats were shown to be effective for ablation of these "unmappable VTs". Bundle branch reentry tachycardia occur in patients with nonischemic cardiomyopathies, mostly valvular heart disease and can be successfully abolished with RF ablation of the right bundle. However, some of these patients may develop recurrences due to other types of VT. Recent technical developments have increased efficacy and simplified the approach of RF ablation of VT in patients with structural heart disease. However, long-term efficacy is not accurately predictable and implantation of an ICD is mandatory in most of the patients with severely depressed left ventricular function.

Cardiomyopathy, Dilated↗

PubMed2001

[Ventricular tachycardia].

In patients with ventricular tachycardias, various structural and functional conditions can be influenced by certain triggers, initiating the mechanism of the arrhythmia. Thorough understanding of these different factors is paramount for the appropriate choice of treatment. Several options are available for the management of ventricular tachycardias: antiarrhythmic drugs, ICD implantation and catheter ablation or a combination of the above. The prognosis of an individual patient is determined by the underlying disease, the mechanism of tachycardia and the selected therapy. The complexity of several conditions requires a specialized diagnostic approach and tailored medical management. Therefore the patients with the following diagnoses should be referred to a specialized electrophysiology center: survivors of sudden cardiac death old infarct scar, reduced ejection fraction and complex ectopy Cardiomyopathy with syncope or ventricular tachycardias Long QT-Syndrome Brugada Syndrome Right Ventricular Dysplasia recurrent syncopes of unclear etiology.

Anti-Arrhythmia Agents↗

PubMed1990

Role of transmitral blood flow velocity by Doppler echocardiography in the evaluation of coronary artery disease.

To determine the relation between presence and severity of coronary artery disease and diastolic filling abnormalities by Doppler echocardiography, recordings of transmitral inflow velocity were made at rest in 90 patients with coronary artery disease and 28 normals. At the time of the Doppler examination, 81 patients with coronary artery disease (90%) and 10 normals (36%) were treated with antianginal medications. No difference was found in the ratio between early (E) and late (A) diastolic filling velocity (E/A ratio) when comparing patients with greater than 70% obstruction of at least one coronary artery to age-matched normals, regardless of the presence or absence of wall motion abnormalities. The E/A ratio was 1.3 +/- 0.46 in coronary patients with normal wall motion, 1.2 +/- 0.47 in coronary patients with abnormal wall motion, and 1.3 +/- 0.53 in both samples of age-matched normals. Multivariate analysis of the relation between E/A ratio and other variables showed that heart rate (F = 24.46, p less than 0.00001) and age (F = 19.51, p less than 0.00001) were significant independent determinants of the E/A ratio, while the presence or severity of coronary artery disease, the presence of hypertension, the magnitude of wall motion abnormalities, and end-diastolic dimension by echocardiography were not. These data suggest that transmitral inflow velocity recordings by Doppler have limited value for the recognition of coronary artery disease, since the E/A ratio is profoundly influenced by other factors, such as heart rate and age.

Adult↗